David Haen

Shares of the Dutch diagnostic test manufacturer Qiagen popped after it confirmed ongoing buyout discussions with Thermo Fisher Scientific and others.

This global pharmaceutical company has a healthy dividend and a bevy of new drugs set to enter the market in the coming years.

Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future.

Wish you could invest in private equity? Business development companies provide a unique, high-yield avenue that lets you co-invest with the titans of Wall Street.

Snapping a downward trend since spring, recent developments have breathed new life into Exelixis’ stock.

Medtronic touts an admirable run of increasing its dividend over 42 consecutive years. But, is the dividend enough for investors to get excited today?

FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.

Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?

No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.

It’s full steam ahead with a slate of late-stage clinical trial results expected in 2020. However, Corbus just released its third-quarter results, and the financial picture looks bleak.

Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.

BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?

Keeping up with the news from major medical meetings has become a requirement for healthcare investors.

The company reclaimed rights to several promising drug candidates last week; this week, positive data from a pivotal clinical trial sent it soaring.

Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.

With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.